Elias M. Stein

Stein in 2008 Elias Menachem Stein (January 13, 1931 – December 23, 2018) was an American mathematician who was a leading figure in the field of harmonic analysis. He was the Albert Baldwin Dod Professor of Mathematics, Emeritus, at Princeton University, where he was a faculty member from 1963 until his death in 2018. Provided by Wikipedia
Showing 1 - 6 results of 6 for search 'E. M. Stein', query time: 0.04s Refine Results
  1. 1
    P505: SAFETY AND EFFICACY OF CASEIN KINASE 1Α AND CYCLIN DEPENDENT KINASE 7/9 INHIBITION IN PATIENTS WITH RELAPSED OR REFRACTORY AML: A PHASE 1, FIRST-IN-HUMAN STUDY OF BTX-A51

    P505: SAFETY AND EFFICACY OF CASEIN KINASE 1Α AND CYCLIN DEPENDENT KINASE 7/9 INHIBITION IN PATIENTS WITH RELAPSED OR REFRACTORY AML: A PHASE 1, FIRST-IN-HUMAN STUDY OF BTX-A51 by B. J. Ball, G. Borthakur, A. Stein, K. W. Chan, D. Thai, E. M. Stein

    Published 2022-06-01
    Get full text
    Article
  2. 2
    PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

    PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSI... by N. G. Daver, A. H. Wei, E. M. Stein, D. J. DeAngelo, D. Pathak, Y. Xu, S. Grzesiak, A. Venditti

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P524: PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML (KB-LANRA 1001)

    P524: PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R... by E. M. Stein, A. Patel, L. C. Michaelis, G. Schiller, R. Swords, L. A. Carvajal, G. Bray, J. DiMartino, M. Y. Levy

    Published 2022-06-01
    Get full text
    Article
  4. 4
    P525: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ENTOSPLETINIB ADDED TO INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN NEWLY DIAGNOSED NPM1-MUTATED AML

    P525: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ENTOSPLETINIB ADDED TO INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN NEWLY D... by J. C. Byrd, J. E. Cortes, M. D. Minden, T. Oellerich, E. M. Stein, J. Elder, P. Kumar, G. Bray, J. DiMartino, W. Stock

    Published 2022-06-01
    Get full text
    Article
  5. 5
    P582: FIRST RESULTS OF A PHASE II STUDY (STIMULUS-AML1) INVESTIGATING SABATOLIMAB + AZACITIDINE + VENETOCLAX IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

    P582: FIRST RESULTS OF A PHASE II STUDY (STIMULUS-AML1) INVESTIGATING SABATOLIMAB + AZACITIDINE + VENETOCLAX IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA by A. M. Zeidan, J. Westermann, T. Kovacsovics, S. Assouline, A. C. Schuh, H.-J. Kim, G. Rodriguez Macias, D. Sanford, M. R. Luskin, E. M. Stein, K. Malek, J. Lyu, M. Stegert, J. Esteve

    Published 2022-06-01
    Get full text
    Article
  6. 6
    P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS)

    P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS) by C. D. DiNardo, J. M. Foran, J. M. Watts, E. M. Stein, S. de Botton, A. T. Fathi, G. T. Prince, R. M. Stone, P. A. Patel, G. J. Roboz, M. L. Arellano, H. P. Erba, A. Pigneux, P. Baratam, R. K. Stuart, X. Thomas, I. R. Lemieux, X. Bai, S. M. Kapsalis, G. Garcia-Manero, D. A. Sallman

    Published 2022-06-01
    Get full text
    Article

Search Tools: